Drugs · acquisition-cost intelligence
Carbamazepin
carbamazepine· ingredient carbamazepine· CARBAMAZEPINE 100 mg/1; CARBAMAZEPINE 100 mg/5mL; CARBAMAZEPINE 200 mg/1; CARBAMAZEPINE 400 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.60091
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 10 weeks.
2025-12-172026-05-27
Same-ingredient options by acquisition cost
Other carbamazepine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Carbamazepine | $0.10059 | −$0.50030 |
| Carbamazepine | $0.12396 | −$0.47700 |
| Epitol | $0.12396 | −$0.47700 |
| Carbamazepine | $0.12396 | −$0.47700 |
| Carbamazepine | $0.12396 | −$0.47700 |
| Carbamazepine | $0.23438 | −$0.36650 |
| Carbamazepine ER | $0.49118 | −$0.10970 |
| carbamazepine | $1.03 | +$0.42730 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 1% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.